For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Tafamidis meglumine represents a significant advancement . These innovative therapies preserve the transthyretin protein, preventing its harmful build-up and less